NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its third-quarter revenues dipped 1.3 percent year over year, with growth in its Research Biotech and fine chemicals (SAFC) businesses being offset by declines in its other units.

The chemicals and lab products firm generated total revenues of $533.8 million for the three-month period ended Sept. 30, compared to revenues of $540.6 million for the third quarter of 2008. Excluding the negative impact of currency translation, Sigma-Aldrich's sales grew around 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.